Harvest Portfolios Group Inc. Raises Stake in Sanofi (NASDAQ:SNY)

Harvest Portfolios Group Inc. lifted its holdings in Sanofi (NASDAQ:SNY) by 4.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,200 shares of the company’s stock after acquiring an additional 1,500 shares during the quarter. Harvest Portfolios Group Inc.’s holdings in Sanofi were worth $2,144,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. POM Investment Strategies LLC purchased a new position in Sanofi during the second quarter valued at $25,000. Larson Financial Group LLC boosted its position in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares during the last quarter. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $29,000. Concord Wealth Partners raised its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the period. Finally, Arrow Financial Corp acquired a new stake in Sanofi during the second quarter worth $35,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 3.0 %

SNY opened at $51.26 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 12 month low of $45.00 and a 12 month high of $58.97. The stock has a market capitalization of $130.09 billion, a P/E ratio of 26.15, a P/E/G ratio of 1.35 and a beta of 0.61. The business has a 50 day simple moving average of $55.78 and a 200-day simple moving average of $52.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. On average, equities analysts anticipate that Sanofi will post 4.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.